<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00917007</url>
  </required_header>
  <id_info>
    <org_study_id>IRBPHS #5803</org_study_id>
    <nct_id>NCT00917007</nct_id>
  </id_info>
  <brief_title>Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis</brief_title>
  <official_title>Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis in ABO-compatible and Incompatible Healthy Term Newborn Infants.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York - Upstate Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York State Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratory Alliance of Central New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York - Upstate Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to more accurately measure the amount of true red blood&#xD;
      cell breakdown (hemolysis) in newborn babies with potentially problematic blood type mismatch&#xD;
      with their mothers (ABO incompatibility), and to examine how the true level of red blood cell&#xD;
      destruction relates to other laboratory tests obtained in newborns with jaundice.&#xD;
&#xD;
      A better understanding of the true amount of red blood cell destruction that is caused by&#xD;
      blood type mismatch, as well as how it relates with other laboratory tests ordered for ABO&#xD;
      incompatibility and red blood cell destruction, would help avoid unnecessary testing,&#xD;
      treatment and prolonged hospital stays in such babies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinically severe jaundice due to ABO incompatibility can occur when infants with blood type&#xD;
      A or B are born to mothers with type O blood. An estimated 20 percent of pregnancies are ABO&#xD;
      incompatible, but only a very small proportion of blood type A or B babies born to O type&#xD;
      mothers develop overt ABO hemolytic disease. Despite the relative rarity of ABO hemolytic&#xD;
      disease, it is common practice among pediatricians and family practice physicians to perform&#xD;
      routine blood typing and antibody screening on all newborns born to type O mothers.&#xD;
&#xD;
      A very accurate and reliable laboratory measure of red blood cell destruction is the plasma&#xD;
      carboxyhemoglobin level (COHb). COHb levels can be determined using a minute amount of blood,&#xD;
      obtained at the same time the newborn's heel is pierced to obtain blood for the mandatory&#xD;
      newborn screen (performed on all newborns prior to discharge) in order to avoid an additional&#xD;
      invasive procedure.&#xD;
&#xD;
      Our hope is to determine whether routine blood typing and anti-globulin testing of infants&#xD;
      born to type O mothers is necessary, or if these tests should instead be obtained only in the&#xD;
      context of significant visible jaundice. This would help clarify the proper management of a&#xD;
      very common problem in the newborn, and minimize the potential for subjecting infants of type&#xD;
      O mothers to unnecessary blood tests, unwarranted treatment, and prolonged hospitalizations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    PI no longer at institution&#xD;
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>ABO Incompatibility</condition>
  <condition>Hemolytic Disease of Newborn</condition>
  <condition>Neonatal Jaundice</condition>
  <condition>Neonatal Hyperbilirubinemia</condition>
  <arm_group>
    <arm_group_label>ABO compatible</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ABO incompatible, antiglobulin positive</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ABO incompatible, antiglobulin negative</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        healthy term newborn infants of mothers with type O blood type&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  mother blood type O&#xD;
&#xD;
          -  mother Rh +&#xD;
&#xD;
          -  healthy infants&#xD;
&#xD;
          -  ≥37 wks gestation&#xD;
&#xD;
          -  ≥ 2500 gm birth weight&#xD;
&#xD;
          -  Apgar ≥5 at 1 and 5 minutes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  major anomalies&#xD;
&#xD;
          -  infants evaluated for sepsis or infants with transitional respiratory problems&#xD;
             requiring &gt;6 hrs observation in the NICU&#xD;
&#xD;
          -  significant birth trauma with continued bruising and/or sequestration of blood still&#xD;
             evident at the time of discharge&#xD;
&#xD;
          -  known perinatal blood loss with hemodynamic consequences such as persistent&#xD;
             tachycardia, need for fluid boluses or supplemental oxygen&#xD;
&#xD;
          -  neonatal anemia with Hb&lt;13.5g/dL&#xD;
&#xD;
          -  known family history of hereditary hemolytic disease such as G6PD deficiency,&#xD;
             hereditary spherocytosis or hereditary elliptocytosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard H Sills, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY Upstate Medical Univeristy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Crouse Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2009</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <name_title>Richard H. Sills, MD</name_title>
    <organization>SUNY Upstate Medical University Dept of Pediatrics</organization>
  </responsible_party>
  <keyword>ABO incompatibility</keyword>
  <keyword>hemolysis</keyword>
  <keyword>jaundice</keyword>
  <keyword>hyperbilirubinemia</keyword>
  <keyword>newborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythroblastosis, Fetal</mesh_term>
    <mesh_term>Hyperbilirubinemia, Neonatal</mesh_term>
    <mesh_term>Jaundice, Neonatal</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Hyperbilirubinemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

